Highlights Mind Medicine (MindMed) Inc. Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Real-time Estimate Tradegate Other stock markets 04:08:24 18/07/2024 pm IST			5-day change	1st Jan Change
7.643 ^EUR	-0.61%		+16.92%	+123.55%

17/07	Mind Medicine Says New Patent Secured for Investigational Anxiety Disorder Treatment MM120	MT
17/07	Mind Medicine Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mind Medicine Says New Patent Secured for Investigational Anxiety Disorder Treatment MM120	17/07	MT
Mind Medicine Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet	17/07	CI
Mind Medicine to Join Russell 2000, 3000 Indexes	28/06	MT
Mind Medicine Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder	20/06	CI
Sector Update: Health Care Stocks Steady Premarket Wednesday	05/06	MT
Top Premarket Decliners	05/06	MT
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	08/03	CI
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	07/03	MT
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	07/03	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	08/01	CI
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	14/12	CI
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	24/23/24	CI
Mind Medicine Completes Enrollment and Dosing in Study Mmed008	12/23/12	CI
Mind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI
Mind Medicine Inc. Provides Overview of Clinical Progress	20/23/20	CI
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy	25/23/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mind Medicine (MindMed) Inc. Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Highlights

Filters